Arax Advisory Partners’s Maravai LifeSciences MRVI Stock Holding History

Arax Advisory Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15	Closed	-$49	–	4141
2025 Q4	$49	Sell	15 -824	-98%	-$2.77K	﹤0.01%	3920
2025 Q3	$2.41K	Buy	+839	New	+$2.14K	﹤0.01%	3074
2025 Q1	–	Sell	-4,063	Closed	-$22.1K	–	2907
2024 Q4	$22.1K	Sell	4,063 -1,509	-27%	-$9.71K	﹤0.01%	1171
2024 Q3	$46.3K	Buy	5,572 +1,332	+31%	+$11.5K	﹤0.01%	749
2024 Q2	$30.4K	Buy	+4,240	New	+$36.6K	﹤0.01%	832
2023 Q1	–	Sell	-118	Closed	-$1.69K	–	1300
2022 Q4	$1.69K	Hold	118	–	–	﹤0.01%	971
2022 Q3	$3K	Hold	118	–	–	﹤0.01%	917
2022 Q2	$3K	Hold	118	–	–	﹤0.01%	902
2022 Q1	$4K	Hold	118	–	–	﹤0.01%	836
2021 Q4	$5K	Hold	118	–	–	﹤0.01%	765
2021 Q3	$6K	Sell	118 -145	-55%	-$7.07K	﹤0.01%	738
2021 Q2	$11K	Buy	+263	New	+$10.2K	﹤0.01%	653

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arax Advisory Partners's MRVI Position: Q1 2026 in Review

Arax Advisory Partners sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 15 shares — an estimated $49 sold.

Arax Advisory Partners first reported a position in MRVI in Q2 2021 and held it in 12 quarters. The position peaked at $46.3K in Q3 2024. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

Arax Advisory Partners reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
Arax Advisory Partners sold 15 Maravai LifeSciences shares in Q1 2026, an estimated $49.
Arax Advisory Partners first reported a position in Maravai LifeSciences in Q2 2021 and held it in 12 quarters.
Arax Advisory Partners's Maravai LifeSciences position peaked at $46.3K in Q3 2024.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.